FGP
EWTX icon

Freestone Grove Partners’s Edgewise Therapeutics EWTX Stock Holding History

Freestone Grove Partners’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-148,426
Closed -$4.68M – 1132
2026
Q1 		$4.68M Buy
+148,426
New +$4.28M 0.03% 326

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Freestone Grove Partners's EWTX Position: Q2 2026 in Review

Freestone Grove Partners sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 148,426 shares — an estimated $4.68M sold.

Freestone Grove Partners first reported a position in EWTX in Q1 2026 and held it in 1 quarter. The position peaked at $4.68M in Q1 2026. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Freestone Grove Partners reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 148,426 Edgewise Therapeutics shares in Q2 2026, an estimated $4.68M.
  • Freestone Grove Partners first reported a position in Edgewise Therapeutics in Q1 2026 and held it in 1 quarter.
  • Freestone Grove Partners's Edgewise Therapeutics position peaked at $4.68M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.